검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg) Ferring Pharmaceuticals·IFNα2b (adenoviral) ORR 55% | Fluorouracil (Fluorouracil) Janssen Research & Development, LL…·Muscle Invasive Bladder Carcinoma ORR 80% | |||
|---|---|---|---|---|---|
Overview Program | Disitamab Vedotin (RC48) | Enfortumab Vedotin | Adstiladrin (nadofaragene firadenovec) | Fluorouracil | Tremelimumab |
Overview Company | RemeGen | Astellas / Seagen | Ferring Pharmaceuticals | Janssen Research & Development, LLC | AstraZeneca |
Overview Modality | ADC | ADC | CGT | ANTIBODY | ANTIBODY |
Overview Target | HER2 | Renal Pelvis and Ureter Urothelial Carci | IFNα2b (adenoviral) | Muscle Invasive Bladder Carcinoma | Muscle Invasive Bladder Cancer |
Overview Indication | HER2+ urothelial, gastric, breast | Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) | Advanced or Metastatic Colorectal Cancer | Hepatocellular Carcinoma |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Overview Status | ACTIVE | RECRUITING | APPROVED | RECRUITING | RECRUITING |
MoA Mechanism | HER2-mediated delivery of MMAE | ADC, while the AKR1C1-WWP2 axis promotes extracellular vesicle-mediated ADC export and clearance, thereby reducing intracellular payload accumulation | Adenoviral transduction of urothelium → local IFNα2b expression → antitumor immunity | inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen |
MoA Biomarker | HER2 expression | biomarkers are limited | CR rate, duration of response | biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t | biomarkers for dual immune checkpoint blockade remain insufficiently defined |
PK/PD Half-life | ~5 days | 3.6 h | — | — | 16.9 h |
PK/PD Species | Mouse | Mouse, Human | Mouse | Mouse | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro | Human, Mouse, In vitro | Mouse, In vitro | Mouse | Mouse |
PK/PD Experiment | PD | Pharmacokinetic | pharmacodynamic | PD | PD |
Toxicology Species | Mouse | Cynomolgus monkey, Mouse, Rat, Human | Cynomolgus monkey, Mouse | Mouse, Human | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro | Mouse, Rat, NHP | NHP | Human | Unknown |
Toxicology Major finding | thrombocytopenia, demonstrated for Kadcyla and Enhertu | Interstitial Lung Disease (ILD): Severe, life-threatening or fatal pneumonitis/ILD may occur | — | thrombocytopenia, inflammation of the esophagus, stomach, and small bowel | pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinop |
Clinical Primary efficacy | ORR 50% | ORR 44% | ORR 55% | ORR 80% | ORR 47% |
Clinical ORR | ~50% in HER2+ UC | 39% | 55% | 80.0% | 47% |
Clinical PFS | 6.9 mo | 5.8 | — | — | — |
Clinical OS | — | 12.4 | 100 | — | — |
Clinical Result source | RC48-C009 | ClinicalTrials.gov NCT03219333 | ClinicalTrials.gov NCT02773849 | ClinicalTrials.gov NCT04430738 | ClinicalTrials.gov NCT02879318 |
Clinical Data Tier / Score | S · 89 | A · 88 | B · 78 | C · 70 | C · 58 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Clinical Dose / schedule | q2w | — | q3 months (label) | — | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 12일 (1일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg) Ferring Pharmaceuticals·IFNα2b (adenoviral) ORR 55% | Fluorouracil (Fluorouracil) Janssen Research & Development, LL…·Muscle Invasive Bladder Carcinoma ORR 80% | |||
|---|---|---|---|---|---|
Overview Program | Disitamab Vedotin (RC48) | Enfortumab Vedotin | Adstiladrin (nadofaragene firadenovec) | Fluorouracil | Tremelimumab |
Overview Company | RemeGen | Astellas / Seagen | Ferring Pharmaceuticals | Janssen Research & Development, LLC | AstraZeneca |
Overview Modality | ADC | ADC | CGT | ANTIBODY | ANTIBODY |
Overview Target | HER2 | Renal Pelvis and Ureter Urothelial Carci | IFNα2b (adenoviral) | Muscle Invasive Bladder Carcinoma | Muscle Invasive Bladder Cancer |
Overview Indication | HER2+ urothelial, gastric, breast | Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) | Advanced or Metastatic Colorectal Cancer | Hepatocellular Carcinoma |
Overview Phase | APPROVED | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Overview Status | ACTIVE | RECRUITING | APPROVED | RECRUITING | RECRUITING |
MoA Mechanism | HER2-mediated delivery of MMAE | ADC, while the AKR1C1-WWP2 axis promotes extracellular vesicle-mediated ADC export and clearance, thereby reducing intracellular payload accumulation | Adenoviral transduction of urothelium → local IFNα2b expression → antitumor immunity | inhibits GC cell proliferation and induces apoptosis by regulating cell-cycle checkpoints and inhibiting oncogenic pathway | targeting antigens like GPC3, AFP, and PD-L1, have been engineered to address antigen |
MoA Biomarker | HER2 expression | biomarkers are limited | CR rate, duration of response | biomarker for metabolic state, B-cell/TLS-associated immune features, and vulnerability to DNA damage-based t | biomarkers for dual immune checkpoint blockade remain insufficiently defined |
PK/PD Half-life | ~5 days | 3.6 h | — | — | 16.9 h |
PK/PD Species | Mouse | Mouse, Human | Mouse | Mouse | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro | Human, Mouse, In vitro | Mouse, In vitro | Mouse | Mouse |
PK/PD Experiment | PD | Pharmacokinetic | pharmacodynamic | PD | PD |
Toxicology Species | Mouse | Cynomolgus monkey, Mouse, Rat, Human | Cynomolgus monkey, Mouse | Mouse, Human | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro | Mouse, Rat, NHP | NHP | Human | Unknown |
Toxicology Major finding | thrombocytopenia, demonstrated for Kadcyla and Enhertu | Interstitial Lung Disease (ILD): Severe, life-threatening or fatal pneumonitis/ILD may occur | — | thrombocytopenia, inflammation of the esophagus, stomach, and small bowel | pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinop |
Clinical Primary efficacy | ORR 50% | ORR 44% | ORR 55% | ORR 80% | ORR 47% |
Clinical ORR | ~50% in HER2+ UC | 39% | 55% | 80.0% | 47% |
Clinical PFS | 6.9 mo | 5.8 | — | — | — |
Clinical OS | — | 12.4 | 100 | — | — |
Clinical Result source | RC48-C009 | ClinicalTrials.gov NCT03219333 | ClinicalTrials.gov NCT02773849 | ClinicalTrials.gov NCT04430738 | ClinicalTrials.gov NCT02879318 |
Clinical Data Tier / Score | S · 89 | A · 88 | B · 78 | C · 70 | C · 58 |
Clinical Program phase | APPROVED | APPROVED | APPROVED | PHASE_3 | PHASE_3 |
Clinical Dose / schedule | q2w | — | q3 months (label) | — | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 12일 (1일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) |
추천 비교
추천 비교